EP
TERN

Eversept Partners’s Terns Pharmaceuticals TERN Stock Holding History

Eversept Partners’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-286,266
Closed -$1.95M – 80
2024
Q2 		$1.95M Buy
286,266
+3,232
+1% +$19.6K 0.13% 65
2024
Q1 		$1.86M Buy
+283,034
New +$1.85M 0.12% 63

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Eversept Partners's TERN Position: Q3 2024 in Review

Eversept Partners sold out of Terns Pharmaceuticals (TERN) in Q3 2024, closing a stake of 286,266 shares — an estimated $1.95M sold.

Eversept Partners first reported a position in TERN in Q1 2024 and held it in 2 quarters. The position peaked at $1.95M in Q2 2024. 156 funds tracked by Wall St. Rank hold TERN as of Q3 2024.

  • Eversept Partners reported no remaining Terns Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Eversept Partners sold 286,266 Terns Pharmaceuticals shares in Q3 2024, an estimated $1.95M.
  • Eversept Partners first reported a position in Terns Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Eversept Partners's Terns Pharmaceuticals position peaked at $1.95M in Q2 2024.
  • 156 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2024.

Based on Eversept Partners's 13F filing for Q3 2024, filed 14 Nov 2024.